Study #2018-0253
A Phase II Study of Lenvatinib in Combination with Everolimus in Patients with Advanced Carcinoid Tumors
MD Anderson Study Status
Not Accepting
Treatment Agent
Everolimus, Lenvatinib
Description
This phase II trial studies how well lenvatinib and everolimus work in treating patients with carcinoid tumors that have spread to other places in the body (advanced) and cannot be removed by surgery (unresectable). Lenvatinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm, Multiple Endocrine Neoplasia Type 1, Neuroendocrine Neoplasm, Unresectable Carcinoid Tumor
Study phase:
Phase II
Physician name:
Arvind Nageshwara Vijaya Dasari
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-855-900-1058
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.